Form 8-K - Current report:
SEC Accession No. 0000950170-25-038737
Filing Date
2025-03-13
Accepted
2025-03-13 16:10:11
Documents
13
Period of Report
2025-03-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K elvn-20250313.htm   iXBRL 8-K 47965
2 EX-99.1 elvn-ex99_1.htm EX-99.1 181238
3 GRAPHIC img107523686_0.jpg GRAPHIC 111628
  Complete submission text file 0000950170-25-038737.txt   512168

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT elvn-20250313.xsd EX-101.SCH 26049
15 EXTRACTED XBRL INSTANCE DOCUMENT elvn-20250313_htm.xml XML 4931
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

EIN.: 811523849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39247 | Film No.: 25735846
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)